Full Press Release Details
Eidos Therapeutics Initiates First Clinical Study For AG10 Targeting Transthyretin Amyloidosis, Appoints Camille Landis As Chief Business Officer.
BBIO
Eidos Therapeutics Initiates First Clinical Study For AG10 Targeting Transthyretin Amyloidosis, Appoints Camille Landis As Chief Business Officer
Key Takeaway: Eidos Therapeutics Initiates First Clinical Study For AG10 Targeting Transthyretin Amyloidosis, Appoints Camille Landis As Chief Business Officer
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis